Loading
LOADING
A side-by-side look at three generations of incretin-based research compounds — single, dual, and triple receptor agonism — and what the trial data documents.
The metabolic peptide research space has produced three generations of clinically-evaluated compounds, each adding a receptor target to its predecessor:
Each generation has produced larger effects on body weight, glucose handling, and metabolic markers than the previous. Comparing them directly — using head-to-head trial data where it exists, and matched trial designs where it does not — provides insight into both how the field has progressed and what mechanistic features drive efficacy.
Before comparing efficacy, the mechanism differences matter:
Semaglutide is a GLP-1 receptor agonist with 94% structural homology to native human GLP-1. Three modifications confer DPP-4 resistance and albumin binding, producing a roughly 7-day half-life suitable for once-weekly administration.
Tirzepatide activates both GLP-1 and GIP receptors. GIP receptor activation contributes complementary effects on insulin sensitivity, lipid metabolism, and appetite regulation through pathways distinct from GLP-1.
Retatrutide adds glucagon receptor activation. Glucagon classically raises blood glucose, but it also increases energy expenditure and mobilizes hepatic lipids. In the context of GLP-1 agonism (which counters glucagon's glucose effects), the net result is metabolic activation without glucose compromise.
Mechanism complexity has increased monotonically: 1 → 2 → 3 receptors. So has efficacy.
Tirzepatide vs Semaglutide. The most informative direct comparison is the SURMOUNT-5 trial (2025 NEJM publication), which directly compared tirzepatide with semaglutide in adults with obesity. At 72 weeks, tirzepatide produced mean weight reductions of approximately 20.2% versus 13.7% for semaglutide — a difference of ~6.5 percentage points favoring tirzepatide.
The earlier SURPASS-2 trial (2021 NEJM) had compared tirzepatide with semaglutide in patients with type 2 diabetes, documenting similar relative differences in weight reduction and superior HbA1c improvements with tirzepatide.
Retatrutide vs the others. No published head-to-head trials directly compare retatrutide with tirzepatide or semaglutide. The available retatrutide data comes from the standalone Phase 2 trial (NCT04881760), so comparisons must be cross-trial — using matched populations, durations, and endpoints to draw inferences.
This is methodologically weaker than direct comparison. Cross-trial inferences can be misleading due to differences in trial populations, run-in periods, dropout handling, and other factors. With that caveat, the available data:
The pattern is consistent with progressively larger effects from each additional receptor mechanism, but the trial durations differ and direct comparison would be needed to definitively establish ordering.
Across these compounds, all three produce meaningful improvements in glucose handling, though the magnitude differs:
The glucose effects are not simply proportional to weight loss — incretin-based compounds produce HbA1c reductions through both weight-independent (direct insulin secretion) and weight-dependent pathways.
Adverse event profiles are broadly similar across the three compounds, with the most common events being gastrointestinal (nausea, vomiting, diarrhea, constipation). Some distinctions worth noting:
Semaglutide. Nausea rates approximately 20-25% at maximum doses. Most adverse events occur during dose escalation and attenuate with sustained dosing. Long-term safety has the most extensive characterization.
Tirzepatide. Nausea rates approximately 24-30% at maximum doses. The GIP component does not appear to introduce significantly different adverse events compared to GLP-1 alone, despite the additional receptor target.
Retatrutide. Nausea rates approximately 35-45% at the highest doses. The glucagon component appears to contribute to additional findings:
Whether the additional adverse events with retatrutide are tolerable in clinical practice will be answered by Phase 3 trial discontinuation rates and post-marketing data.
All three compounds are designed for once-weekly subcutaneous administration:
The pharmacokinetic profiles are designed for the same dosing convenience. Oral formulations of semaglutide exist (Rybelsus) and an oral GLP-1 agonist (orforglipron) is in Phase 3 development — oral formulations of tirzepatide and retatrutide have not been reported.
The progression from single to dual to triple receptor agonism has not produced linear increases in efficacy. The data suggests:
These improvements are meaningful but not multiplicative. This pattern is consistent with each additional receptor target engaging partially overlapping rather than fully independent biology — the additional mechanism captures effect that the existing receptors did not fully address, but does not multiply the existing effect.
This has implications for further-generation compounds. Quadruple agonists (adding amylin or other targets to triple agonism) might produce incremental rather than transformative gains.
For interpretation of published research:
Trial design matters more than receptor count. Effect sizes reported are highly dependent on trial duration, dose escalation protocols, run-in periods, and participant population. Compare matched designs where possible.
Plateau patterns differ. Semaglutide and tirzepatide trial curves show clear plateauing at 60-72 weeks. Retatrutide curves at 48 weeks have not plateaued — longer-duration data may show larger total reductions than the current Phase 2 numbers suggest.
Discontinuation data is critical. All three compounds produce substantial weight regain after discontinuation. The proportion of effect that is "maintained" versus dependent on continued administration is similar across compounds, suggesting the underlying obesity biology is broadly common rather than mechanism-specific.
Across three generations of incretin-based research, each adding a receptor target has produced larger effects than the previous, with retatrutide currently representing the largest single-compound effect size documented in obesity research. Whether this represents the ceiling of mechanism-based research, the beginning of a quadruple-agonist generation, or a turning point toward novel mechanisms entirely will be determined by ongoing Phase 3 trials and the next wave of clinical development.
What is clear from the existing data is that the addition of each receptor target has produced consistent if diminishing improvements in efficacy, with safety profiles that have remained broadly similar despite increasing mechanistic complexity.
NoteThis article is intended for informational and educational purposes only. It does not constitute medical advice.
Still have questions?
ASK AXIOM ABOUT THIS TOPIC →